Xenova HPV vaccine results

Xenova (LSE:XEN; XNVA) said that in a U.K. Phase IIa trail of TA-HPV vaccine in women with high grade vulval intra-epithelial neoplasia (VIN 3), 8 of 18 patients (44%) had objective clinical responses at 6 months, as measured by a 50% or greater reduction of lesions and pathology. Four patients (22%) showed symptom relief. VIN 3 is an ano-genital intraepithelial neoplasia (AGIN) associated with human papillomavirus (HPV). ...